City Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
City Therapeutics, Inc. Common Stock cash flow-to-debt ratio. City Therapeutics, Inc. Common Stock (CTY) has a Cash Flow-to-Debt Ratio of 0.07x as of June 2020, meaning its operating cash flow of $699.00 Million could theoretically repay 0% of its total liabilities ($9.32 Billion) in one year. Check City Therapeutics, Inc. Common Stock cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of City Therapeutics, Inc. Common Stock (2005–2025)
Cash flow-to-debt ratio of City Therapeutics, Inc. Common Stock from 2005 to 2025. Historical debt coverage capacity for City Therapeutics, Inc. Common Stock across 17 annual periods. Check City Therapeutics, Inc. Common Stock investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
City Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2005–2025)
City Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2005 to 2025. Year-by-year debt coverage analysis for City Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see City Therapeutics, Inc. Common Stock operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.18x | $-41.61 Million | $234.42 Million | ▼ -52.1% |
| 2024 | -0.12x | $-20.39 Million | $174.78 Million | ▼ -138.1% |
| 2019 | 0.31x | $3.33 Billion | $10.88 Billion | ▼ -13.5% |
| 2018 | 0.35x | $3.79 Billion | $10.71 Billion | ▲ +67.6% |
| 2017 | 0.21x | $2.44 Billion | $11.53 Billion | ▼ -0.8% |
| 2016 | 0.21x | $2.65 Billion | $12.46 Billion | ▲ +3.2% |
| 2015 | 0.21x | $2.59 Billion | $12.56 Billion | ▼ -2.3% |
| 2014 | 0.21x | $2.80 Billion | $13.27 Billion | ▲ +5.8% |
| 2013 | 0.20x | $2.71 Billion | $13.61 Billion | ▲ +0.4% |
| 2012 | 0.20x | $2.77 Billion | $13.97 Billion | ▲ +35.7% |
| 2011 | 0.15x | $2.20 Billion | $15.04 Billion | ▼ -34.4% |
| 2010 | 0.22x | $3.23 Billion | $14.52 Billion | ▲ +3.6% |
| 2009 | 0.22x | $3.17 Billion | $14.73 Billion | ▼ -9.4% |
| 2008 | 0.24x | $3.48 Billion | $14.66 Billion | ▲ +5.0% |
| 2007 | 0.23x | $3.26 Billion | $14.42 Billion | ▲ +6.4% |
| 2006 | 0.21x | $3.13 Billion | $14.74 Billion | ▼ -5.2% |
| 2005 | 0.22x | $3.42 Billion | $15.23 Billion | — |